Valneva SE (FRA:AYJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 479.91M -7.1% |
| Revenue (ttm) | 174.66M +3.0% |
| Net Income | -115.19M |
| EPS | -0.68 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,289 |
| Average Volume | 17,775 |
| Open | 2.796 |
| Previous Close | 2.834 |
| Day's Range | 2.770 - 2.842 |
| 52-Week Range | 2.176 - 5.300 |
| Beta | n/a |
| RSI | 23.97 |
| Earnings Date | Mar 18, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial StatementsNews
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will t...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact D...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to conta...
Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges
Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Lyme disease vaccine 70 percent effective: Pfizer
A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be the ...
Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial
Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the com...
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions. ... Full story available on Benzinga.com
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the resul...
Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy
(RTTNews) - Valneva SE (VALN) saw its stock drop sharply, even as the company and partner Pfizer announced that their Lyme disease vaccine candidate demonstrated more than 70% efficacy in a large Phas...
Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 1,000 points on Monday. Shares of Valneva SE (NASDAQ: VALN) fell sharply in pre- market trading . Pfizer (NYSE: PFE) ...
Pfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial
(RTTNews) - Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its investigational 6-valent OspA-based Lyme di...
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Ou...
Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Full Year 2025 Valneva SE Earnings Call Transcript
Full Year 2025 Valneva SE Earnings Call Transcript
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology
Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology
Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. Shares of Clearpoint Neuro Inc (NASDAQ: CLPT) fell sharply in pre-market trading after the co...
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive globa...
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ: SAIL) is estimated to report quarterly earnings at $0.08 per share on revenue of $292.61 million. • InspireMD (NASDAQ: NSPR) is expected to r...
Valneva Reports Audited FY25 Results Ahead Of Full Presentation Later Today
(RTTNews) - Valneva SE (VALN), a specialty vaccine company, reported its audited consolidated financial results for the full-year 2025, reaffirming its revenue performance and strengthened cash positi...